Quick Answer
Aclaris Therapeutics, Inc. reported Operating Income of -$76.38 million for fiscal year 2025.
Aclaris Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$76.38M | +46.2% |
| 2024 | -$141.93M | -45.8% |
| 2023 | -$97.36M | -8.4% |
| 2022 | -$89.85M | -0.1% |
| 2021 | -$89.72M | -76.2% |
| 2020 | -$50.91M | +54.2% |
| 2019 | -$111.06M | -31.0% |
| 2018 | -$84.78M | -56.0% |
| 2017 | -$54.36M | -11.9% |
| 2016 | -$48.57M | -135.0% |
| 2015 | -$20.67M | -142.2% |
| 2014 | -$8.53M | -62.3% |
| 2013 | -$5.26M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$17.15M | -63.8% | +6.8% |
| June 30, 2025 | -$18.41M | -43.2% | -1.8% |
| March 31, 2025 | -$18.08M | +4.5% | -72.7% |
| September 30, 2024 | -$10.47M | +66.8% | +18.5% |
| June 30, 2024 | -$12.85M | +59.6% | +32.1% |
| March 31, 2024 | -$18.93M | +36.7% | +40.0% |
| September 30, 2023 | -$31.58M | -51.3% | +0.7% |
| June 30, 2023 | -$31.82M | -51.5% | -6.3% |
- Aclaris Therapeutics, Inc. showed an increase of +46.2% in Operating Income compared to the prior fiscal year.
- Over the 2013–2025 period, Aclaris Therapeutics, Inc.’s operating income has declined by 1352.8% (from -$5.26 million to -$76.38 million).
- The most recent figure is from Aclaris Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: